HHS: Specialty drug costs up more than $300 billion since 2016

HHS has released two new reports that it said not only “illustrate the urgency of addressing skyrocketing prescription drug costs in America,” but also highlight the potential positive impact of the Inflation Reduction Act.Specifically, the reports show how inflation rebates from the Inflation Reduction Act would protect Medicare beneficiaries from increasing drug costs, according to HHS. One report analyzed trends in prescription drug spending while the other tracked increases in prescription drug prices from 2016 to 2022. The reports were published by HHS’s AssistantRead More

Related Articles